According to an international survey conducted earlier this year, 70% of respondents said they believed tobacco companies make money by selling devices such as inhalers, medication or other equipment to treat lung diseases. The survey findings are published in a new communication brief entitled "Pharmaceutical industry ownership of the tobacco business: An international survey of respiratory disease patients", in the official journal of the British Thoracic Society, Thorax.
At the beginning of 2022, a total of 1,196 individuals who reported using inhalers participated in a survey. Following the acquisition of pharmaceutical company Vectura by Fimo International in 2021, patient advocacy groups sought to understand patients' attitudes towards tobacco companies holding stakes in manufacturers of respiratory inhalation equipment. Vectura has developed several widely-used medical delivery devices and/or formulations for inhalation therapy for chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and asthma.
The COPD Foundation, in collaboration with the Global Allergy and Airways Patient Platform and Lung Foundation Australia, conducted a survey of chronic lung disease patients in January through March 2022 in English, Spanish, and German. In addition to expressing concerns about tobacco ownership of lung treatments, a significant portion (48%) of surveyed patients also indicated that they would strongly consider switching inhalers if they knew tobacco companies manufactured or sold the brand they use.
This was an unexpected discovery, as in my own practice, many patients have expressed a tendency to stick with medications that are effective for them," said Byron Thomashow, Chief Medical Officer of the COPD Foundation and co-author of the Chest brief, in a statement. "However, socioeconomic and systemic factors, such as insurance coverage, healthcare system restrictions, and convenience, strongly impact a patient's ability to make treatment choices.
Statement
This article is compiled from third-party information and is intended for industry professionals for the purposes of learning and sharing information.
This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness or accuracy of the article's content. The translation of this article is only intended for industry communication and research purposes.
Due to limitations in the level of translation, the translated article may not fully express the original text, therefore please refer to the original text for accuracy.
2FIRSTS maintains full alignment with the Chinese government in regard to any domestic, Hong Kong, Macau, Taiwan, or foreign issues and stances.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
